ArticleCase reports in oncology

Divergent Responses to Enfortumab Vedotin and Pembrolizumab in Concurrent Urothelial and Renal Cell Carcinoma: Case Report and Literature Review.

Zane N Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.